Biogen (BIIB), a leading biotechnology company, released its third-quarter earnings on October 23. Biogen surpassed Wall Street analysts’ estimates for EPS and revenues during the quarter. Biogen reported non-GAAP diluted EPS of $7.40 on revenues of ~$3.44 billion. The company beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.
The chart below compares Biogen’s revenues and EPS since the first quarter of 2017.
Revenues in Q3 2018
During the third quarter, Biogen (BIIB) reported 12.0% year-over-year revenue growth to ~$3.44 billion. The strong sales of multiple sclerosis products Tecfidera and Tysabri contributed to the company’s revenue growth during the quarter. Its revenue growth was also aided by robust sales of biosimilars as well as Spinraza, its spinal muscular atrophy product.
Biogen’s revenues from the US markets decreased to $1.74 billion during the third quarter, compared to its revenues of $1.77 billion for the third quarter of 2017. This revenue growth was impacted by lower sales of Interferon and Tysabri in the US markets during the quarter. The company’s US revenue growth was aided substantially by strong sales of Tecfidera and Spinraza.
The company’s revenues from its Rest of the World markets increased to ~$1.04 billion during the third quarter, compared to revenues of $848.5 million in the third quarter of 2017. This revenue growth was driven by strong sales of Tecfidera, Tysabri, Spinraza, Benepali, and Flixabi in its international markets. This growth was partially offset by lower sales of Interferon, Fampyra, and Fumaderm.
The Invesco Dynamic Biotechnology & Genome ETF (PBE) holds 5.1% of its total investments in Biogen (BIIB), 5.6% in Amgen (AMGN), 5.4% in Vertex Pharmaceuticals (VRTX), and 5.4% in Regeneron Pharmaceuticals (REGN).
Today at 1:08 PM ET, Tesla (TSLA) rose 10.2% from its previous closing price as Citron Research turned positive on TSLA for the first time.
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.